DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Oppenheimer Initiates Coverage On aTyr Pharma with Outperform Rating, Announces $8 Price Target

Oppenheimer analyst Hartaj Singh initiates coverage on aTyr Pharma (NASDAQ:LIFE) with a Outperform rating and a $8 price target.

Benzinga · 03/02/2020 15:42

Oppenheimer analyst Hartaj Singh initiates coverage on aTyr Pharma (NASDAQ:LIFE) with a Outperform rating and a $8 price target.